

Sanna-Kaisa Herukka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8764667/publications.pdf>

Version: 2024-02-01

81
papers

3,930
citations

218381

26
h-index

128067

60
g-index

82
all docs

82
docs citations

82
times ranked

6279
citing authors

#	ARTICLE	IF	CITATIONS
1	Threshold of heteroplasmic truncating MT-ATP6 mutation in reprogramming, Notch hyperactivation and motor neuron metabolism. <i>Human Molecular Genetics</i> , 2022, 31, 958-974.	1.4	9
2	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
3	Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients. <i>Fluids and Barriers of the CNS</i> , 2022, 19, 11.	2.4	18
4	Circulating neurofilament is linked with morbid obesity, renal function, and brain density. <i>Scientific Reports</i> , 2022, 12, 7841.	1.6	21
5	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 163-175.	1.2	5
6	Elevated CSF LRG and Decreased Alzheimer's Disease Biomarkers in Idiopathic Normal Pressure Hydrocephalus. <i>Journal of Clinical Medicine</i> , 2021, 10, 1105.	1.0	12
7	Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1629-1642.	1.2	10
8	GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1305-1312.	0.9	25
9	A novel CT-based automated analysis method provides comparable results with MRI in measuring brain atrophy and white matter lesions. <i>Neuroradiology</i> , 2021, 63, 2035-2046.	1.1	6
10	Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103280.	0.9	14
11	Neurofilament Light Regulates Axon Caliber, Synaptic Activity, and Organelle Trafficking in Cultured Human Motor Neurons. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 820105.	1.8	23
12	Peripheral inflammatory markers and clinical correlations in patients with frontotemporal lobar degeneration with and without the C9orf72 repeat expansion. <i>Journal of Neurology</i> , 2020, 267, 76-86.	1.8	8
13	Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. <i>Journal of Neurology</i> , 2020, 267, 162-167.	1.8	70
14	Vitamin D supplementation and serum neurofilament light chain in interferon- β -treated MS patients. <i>Brain and Behavior</i> , 2020, 10, e01772.	1.0	7
15	Tau, S100B and NSE as Blood Biomarkers in Acute Cerebrovascular Events. <i>In Vivo</i> , 2020, 34, 2577-2586.	0.6	17
16	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e040152.	0.4	0
17	Differential diagnosis of dementia combining web-based cognitive testing and MRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e042626.	0.4	0
18	Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. <i>Alzheimer's and Dementia</i> , 2020, 16, e042687.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 903-910.	1.7	17
20	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1061-1070.	1.2	13
21	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. <i>PLoS ONE</i> , 2020, 15, e0226784.	1.1	7
22	Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 751-765.	1.2	10
23	Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 277-286.	1.2	13
24	Serum Neurofilament Light in Patients with Frontotemporal Dementia Caused by CHMP2B Mutation. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 533-538.	0.7	7
25	Title is missing!. , 2020, 15, e0226784.		0
26	Title is missing!. , 2020, 15, e0226784.		0
27	Title is missing!. , 2020, 15, e0226784.		0
28	Title is missing!. , 2020, 15, e0226784.		0
29	Low Serum High-Density Lipoprotein Cholesterol Levels Associate with the C9orf72 Repeat Expansion in Frontotemporal Lobar Degeneration Patients. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 127-137.	1.2	13
30	Predicting Development of Alzheimer's Disease in Patients with Shunted Idiopathic Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1233-1243.	1.2	28
31	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	4.9	85
32	[11C]PIB PET Is Associated with the Brain Biopsy Amyloid- β Load in Subjects Examined for Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1343-1351.	1.2	13
33	CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1117-1123.	0.9	61
34	Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2242-2249.	0.7	40
35	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 25.	3.0	23
36	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. <i>Current Alzheimer Research</i> , 2019, 16, 91-101.	0.7	23

#	ARTICLE	IF	CITATIONS
37	BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer's Disease than in Bullous Pemphigoid. <i>Journal of Investigative Dermatology</i> , 2019, 139, 293-299.	0.3	20
38	Subtle Cognitive Impairment and Alzheimer's Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 165-174.	1.2	9
39	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	3.0	40
40	Low Prevalence of Cancer in Patients with Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 789-794.	1.2	9
41	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
42	Association of Cerebral Amyloid- β 2 Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
43	P1-328: CONSISTENCY OF MUISTIKKO WEB-BASED COGNITIVE TEST WHILE PERFORMED AT CLINIC AND AT HOME. <i>Alzheimer's and Dementia</i> , 2018, 14, P418.	0.4	0
44	P1-251: CSF NEUROGRANIN, BUT NOT BACE1, IS AN ALZHEIMER'S DISEASE SPECIFIC BIOMARKER. <i>Alzheimer's and Dementia</i> , 2018, 14, P376.	0.4	0
45	P2-421: THE CORRELATION BETWEEN CSF BIOMARKERS AND VOLUMETRIC ATROPHY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P870.	0.4	0
46	Alterations in mitochondria-endoplasmic reticulum connectivity in human brain biopsies from idiopathic normal pressure hydrocephalus patients. <i>Acta Neuropathologica Communications</i> , 2018, 6, 102.	2.4	19
47	The Association Between Frontotemporal Lobar Degeneration and Bullous Pemphigoid. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 743-750.	1.2	6
48	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 639-652.	1.2	12
49	Prevalence of immunological diseases in a Finnish frontotemporal lobar degeneration cohort with the C9orf72 repeat expansion carriers and non-carriers. <i>Journal of Neuroimmunology</i> , 2018, 321, 29-35.	1.1	19
50	S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid- β 2 Plaques and Tau in Brain Biopsies. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 171-179.	1.2	14
51	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	1.2	10
52	Decreased plasma β 2 amyloid in the Alzheimer's disease <i>APP</i> variant carriers. <i>Annals of Neurology</i> , 2017, 82, 128-132.	2.8	39
53	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	1.5	27
54	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284.	0.4	113

#	ARTICLE	IF	CITATIONS
55	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295.	0.4	108
56	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1387-1395.	1.2	24
57	Increased Levels of the Bullous Pemphigoid BP180 Autoantibody Are Associated with More Severe Dementia in Alzheimer's Disease. <i>Journal of Investigative Dermatology</i> , 2017, 137, 71-76.	0.3	62
58	Preclinical effects of APOE ϵ 4 on cerebrospinal fluid A β 42 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 87.	3.0	22
59	Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 142-149.	0.6	41
60	Low Cerebrospinal Fluid Amyloid-Beta Concentration Is Associated with Poorer Delayed Memory Recall in Women. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 303-312.	0.6	10
61	Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 313-329.	0.6	12
62	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. <i>Scientific Reports</i> , 2016, 6, 26145.	1.6	24
63	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 404-413.	1.1	84
64	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β 2 in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	3.7	107
65	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	1.2	18
66	Multimodal analysis to predict shunt surgery outcome of 284 patients with suspected idiopathic normal pressure hydrocephalus. <i>Acta Neurochirurgica</i> , 2016, 158, 2311-2319.	0.9	21
67	Amyloid- β 2 and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 261-269.	1.2	39
68	Chasing the Effects of Pre-Analytical Confounders – A Multicenter Study on CSF-AD Biomarkers. <i>Frontiers in Neurology</i> , 2015, 6, 153.	1.1	38
69	The CERAD Neuropsychological Battery in Patients with Frontotemporal Lobar Degeneration. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 147-154.	0.6	13
70	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	3.7	284
71	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
72	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1306-1315.	0.4	104

#	ARTICLE	IF	CITATIONS
73	Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. PLoS ONE, 2014, 9, e91974.	1.1	91
74	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85
75	Comparison Between Clinical Diagnosis and CSF Biomarkers of Alzheimer Disease in Elderly Patients with Late Onset Psychosis: Helsinki Old Age Psychosis Study (HOPS). American Journal of Geriatric Psychiatry, 2014, 22, 908-916.	0.6	12
76	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
77	Prognostic Polypeptide Blood Plasma Biomarkers of Alzheimer's Disease Progression. Journal of Alzheimer's Disease, 2014, 40, 659-666.	1.2	44
78	Effects of Alzheimer's Disease-Associated Risk Loci on Cerebrospinal Fluid Biomarkers and Disease Progression: A Polygenic Risk Score Approach. Journal of Alzheimer's Disease, 2014, 43, 565-573.	1.2	49
79	P4-063: APOE GENOTYPE AND CSF A β 42 IN COGNITIVELY HEALTHY INDIVIDUALS. , 2014, 10, P806-P806.		0
80	P1-128: C9ORF72 EXPANSION DOES NOT HAVE EFFECTS ON CSF TDP-43 LEVELS IN FTLD PATIENTS. , 2014, 10, P347-P347.		0
81	O1-01-01: Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy. , 2012, 8, P83-P84.		0